DDInter581 DDInter1476
Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is not shown to have activity at other known serotonin receptors, and has low affinity for dopamine receptors.
Pirbuterol is a beta-2 adrenergic bronchodilator. In vitro studies and in vivo pharmacologic studies have demonstrated that pirbuterol has a preferential effect on beta-2 Adrenergic receptors compared with isoproterenol. While it is recognized that beta-2 adrenergic receptors are the predominant receptors in bronchial smooth muscle, data indicate that there is a population of beta-2 receptors in the human heart, existing in a concentration between 10-50%. The precise function of these receptors has not been established. The pharmacologic effects of beta adrenergic agonist drugs, including pirbuterol, are at least in proof attributable to stimulation through beta adrenergic receptors of intracellular adenyl cyclase, the enzyme which catalyzes the conversion of adenosine triphosphate (AlP) to cyclic-3† ,5†-adenosine monophosphate (c-AMP). Increased c-AMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells.
Dolasetron {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Salbutamol
Salbutamol {u} (Compound) resembles {v} (Compound) Pirbuterol
Dolasetron {u} may lead to a major life threatening interaction when taken with {v} Nadolol
Nadolol {u} (Compound) resembles {v} (Compound) Pirbuterol
Dolasetron {u} (Compound) causes {v} (Side Effect) Dry mouth
Dry mouth {u} (Side Effect) is caused by {v} (Compound) Pirbuterol
Dolasetron {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Salbutamol
Salbutamol {u} (Compound) resembles {v} (Compound) Bupranolol
Bupranolol {u} (Compound) resembles {v} (Compound) Pirbuterol
Dolasetron {u} may lead to a major life threatening interaction when taken with {v} Nadolol
Nadolol {u} (Compound) resembles {v} (Compound) Bupranolol
Bupranolol {u} (Compound) resembles {v} (Compound) Pirbuterol
Dolasetron {u} (Compound) causes {v} (Side Effect) Dry mouth
Dry mouth {u} (Side Effect) is caused by {v} (Compound) Terbutaline
Terbutaline {u} (Compound) resembles {v} (Compound) Pirbuterol
Dolasetron {u} (Compound) causes {v} (Side Effect) Gastrointestinal pain
Gastrointestinal pain {u} (Side Effect) is caused by {v} (Compound) Salbutamol
Salbutamol {u} (Compound) resembles {v} (Compound) Pirbuterol
Dolasetron {u} may lead to a major life threatening interaction when taken with {v} Penbutolol
Penbutolol {u} (Compound) resembles {v} (Compound) Bupranolol
Bupranolol {u} (Compound) resembles {v} (Compound) Pirbuterol
Dolasetron {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Salbutamol
Salbutamol {u} (Compound) resembles {v} (Compound) Terbutaline
Terbutaline {u} (Compound) resembles {v} (Compound) Pirbuterol
Dolasetron {u} may lead to a major life threatening interaction when taken with {v} Nadolol
Nadolol {u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v} Salbutamol
Salbutamol {u} (Compound) resembles {v} (Compound) Pirbuterol
Dolasetron may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol (Compound) resembles Pirbuterol (Compound)
Dolasetron may lead to a major life threatening interaction when taken with Nadolol and Nadolol (Compound) resembles Pirbuterol (Compound)
Dolasetron (Compound) causes Dry mouth (Side Effect) and Dry mouth (Side Effect) is caused by Pirbuterol (Compound)
Dolasetron may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol (Compound) resembles Bupranolol (Compound) and Bupranolol (Compound) resembles Pirbuterol (Compound)
Dolasetron may lead to a major life threatening interaction when taken with Nadolol and Nadolol (Compound) resembles Bupranolol (Compound) and Bupranolol (Compound) resembles Pirbuterol (Compound)
Dolasetron (Compound) causes Dry mouth (Side Effect) and Dry mouth (Side Effect) is caused by Terbutaline (Compound) and Terbutaline (Compound) resembles Pirbuterol (Compound)
Dolasetron (Compound) causes Gastrointestinal pain (Side Effect) and Gastrointestinal pain (Side Effect) is caused by Salbutamol (Compound) and Salbutamol (Compound) resembles Pirbuterol (Compound)
Dolasetron may lead to a major life threatening interaction when taken with Penbutolol and Penbutolol (Compound) resembles Bupranolol (Compound) and Bupranolol (Compound) resembles Pirbuterol (Compound)
Dolasetron may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol (Compound) resembles Terbutaline (Compound) and Terbutaline (Compound) resembles Pirbuterol (Compound)
Dolasetron may lead to a major life threatening interaction when taken with Nadolol and Nadolol (Compound) resembles Salbutamol (Compound) and Nadolol may lead to a major life threatening interaction when taken with Salbutamol and Salbutamol (Compound) resembles Pirbuterol (Compound)